Indrayani Biotech Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025, demonstrating a strong recovery in operational performance. The board meeting held on December 11, 2025, approved comprehensive financial results and significant governance changes.

Financial Performance Overview

The company's consolidated financial performance showed marked improvement across key metrics for Q2FY26:

For the half-year period ended September 30, 2025, the consolidated performance reflected sustained growth momentum with total income reaching ₹6,790.97 lakhs compared to ₹6,268.65 lakhs in the corresponding period of FY25.

Standalone Results Analysis

The standalone financial results presented a different trajectory, showing revenue decline but maintained profitability:

Despite lower standalone revenue, the company achieved significantly higher profitability margins, indicating improved operational efficiency and cost management.

Board Changes and Governance Updates

The board approved several important governance changes during the meeting. Ms. Lakshmiprabha Kasiraman (DIN: 02885912) resigned from her position as Non-executive and Non-Independent Director effective November 13, 2025, citing personal commitments as the reason for resignation.

Following this resignation, the company reconstituted two key committees:

Nomination & Remuneration Committee:

• Dr. Bokara Nagarajan Padmaja Priyadarshini (Chairperson)
• Mr. Kannimangalam Subramanyan Vaidyanathan (Member)
• Mr. Nangavaram Mahadevan Ranganathan (Member)

Stakeholders Relationship Committee:

• Mr. Nangavaram Mahadevan Ranganathan (Chairperson)
• Mr. Kannimangalam Subramanyan Vaidyanathan (Member)
• Dr. Bokara Nagarajan Padmaja Priyadarshini (Member)

Regulatory Compliance and Penalties

The board acknowledged a compliance issue identified by BSE relating to Regulation 6(1) regarding the appointment of a qualified company secretary as compliance officer. The exchange levied a fine of ₹16,520.00 (including GST) for the delayed compliance during the quarter ended September 2025. The company has since appointed the compliance officer and paid the prescribed fine to BSE.

Subsidiary Performance and Consolidation

The consolidated results include financial information from 7 subsidiaries and 2 step-down subsidiaries, which collectively contributed total revenues of ₹5,333.14 lakhs and comprehensive profit of ₹47.26 lakhs for the period ended September 30, 2025. The subsidiary network includes entities such as IBL Health Care Limited, HSL Agri Solutions Limited, and Matrix Boilers Private Limited, among others.

Balance Sheet Strength

The consolidated balance sheet as of September 30, 2025, showed total assets of ₹27,445.71 lakhs compared to ₹26,816.55 lakhs as of March 31, 2025. The company maintained a healthy equity base of ₹10,381.70 lakhs, including non-controlling interests of ₹2,800.19 lakhs. The financial results have been reviewed by statutory auditors Venkatesh & Co, who provided an unmodified opinion on both standalone and consolidated financial statements.

Indrayani Biotech Limited, a Chennai-based company, has taken a significant step towards strengthening its capital structure. The company announced that it has received in-principle approval from BSE Limited for a proposed rights issue of partly paid-up equity shares.

Key Details of the Approval

Company's Disclosure

The company made this announcement through a regulatory filing signed by Swaminathan G, the Whole-time Director of Indrayani Biotech Limited. The approval grants BSE's consent for the proposed rights issue under the Securities and Exchange Board of India (SEBI) listing regulations.

Additional Information

According to the LODR (Listing Obligations and Disclosure Requirements) data:

• The company officially intimated the BSE about the in-principle approval on September 20, 2025.
• The approval falls under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
• Indrayani Biotech Limited is listed on the BSE with the scrip code 526445.

About Indrayani Biotech Limited

Indrayani Biotech Limited is headquartered at Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032. The company's Corporate Identification Number (CIN) is L40100TN1992PLC129301.

This development marks a crucial step for Indrayani Biotech as it moves forward with its capital raising plans. The rights issue, once completed, could provide the company with additional funds for its business operations and growth strategies. Shareholders and potential investors are advised to keep an eye on further announcements regarding the details of the rights issue, including the issue price, rights entitlement ratio, and the timeline for subscription.